![]() ![]() Table 1: Summary of key resource estimates for producing 8 billion doses of mRNA vaccine. The capital cost for retrofitting facilities would be $3.2 billion, while the operating cost for the drug substance production campaign would be $17.5 billion. This would require 4,620 employees working at 55 production lines, which could be set up in 14 facilities. In the case of the NIH-Moderna vaccine, for example, we estimate that producing eight billion doses in one year would cost $23 billion. This entire analysis is presented for the National Institutes of Health-Moderna Covid-19 vaccine (mRNA-1273), the BioNTech-Pfizer Covid-19 vaccine (BNT162b2), and the CureVac vaccine (CVnCoV). ![]() Critically, given the adaptability of mRNA technology, it also would set up the infrastructure required to quickly address variants and future public health threats. This would be enough to cover 80% percent of the population-what some experts believe is necessary for achieving herd immunity-in low- and middle-income countries. Using computational process modelling, we show how the global community could set up regional hubs capable of producing eight billion mRNA vaccine doses by May 2022. In this report, we provide one path forward. What would it take to produce enough coronavirus vaccine for the world in one year? Today, BioNTech’s Marburg facility is producing millions of mRNA vaccine doses a week. But, in less than six months, the team switched from making cancer medicines to pumping out vaccines. The 300 staff at the facility had never worked with the new vaccine technology used by the company. Last September, a biotechnology company bought a manufacturing plant in a small German city. Resources required for producing eight billion doses.Description of the mRNA production process.As part of the GE Healthcare BioProcess™ media platform, Capto ImpRes ion exchangers are manufactured under validated production methods, backed up with Regulatory Support Files, and have Secure Supply routines in place. “Capto ImpRes media have been designed to meet the throughput and high resolution needs of intermediate purification and polishing.”Ĭapto ImpRes media are available in several convenient formats, including Predictor™ 96-well filter plates and prepacked HiTrap™ and HiScreen™ columns to support all stages of biopharmaceutical development and manufacture. “The extension of the Capto platform with Capto ImpRes ion exchangers demonstrates our commitment to supporting biopharmaceutical manufacturers with the most modern tools to improve their processes in terms of throughput, productivity, and economy,” said Dr Nigel Darby, Vice President, Biotechnologies, GE Healthcare. The first Capto ImpRes products to be launched are Capto SP ImpRes and Capto Q ImpRes, strong cation and strong anion exchangers, respectively, that enable high throughput, high resolution polishing, and flexibility in process design.Ĭapto ImpRes media are based on a rigid high-flow agarose matrix that allows the use of high flow rates and higher bed heights, providing biopharmaceutical manufacturers with the possibility to reduce cycle times and maintain or reduce column equipment footprint, thus contributing to driving improvements in process economics. GE Healthcare has extended its Capto™ platform to include Capto ImpRes ion exchange chromatography media for late-stage purification of a wide range of biomolecules. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |